89bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update


– Topline results from ENLIVEN Phase 2b NASH trial on track for first quarter of 2023 –

See the article here:
89bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Related Posts